All these data, taken together highlight the great therapeutic potential of BCP for oral mucositis; in fact it possesses a dual mechanism of action; inhibition of NF-κB and activation of PPAR-γ that amplifies its efficacy in the first phase of inflammation and later it halts, by inhibiting STAT3, the second phase of the inflammatory response. The gene discussed is OPN1SW; the disease is oral mucositis.